Clinical trial
Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
NCT00003183 · Hope Cancer Institute, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00003183 |
|---|---|
| Title | Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer |
| Official title | A Phase I/II Trial Using Weekly Mitoxantrone Chemotherapy and G-CSF for the Treatment of Metastatic Hormone Refractory Prostate Cancer |
| Lead sponsor | Hope Cancer Institute, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, mitoxantrone hydrochloride |
| Enrollment | 64 |
| Start date | Mar 1, 1997 |
| First posted | May 19, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: